---
title: Clinical References and Resources
category: resources
version: 1.0
last_updated: 2025-01
---

# Clinical References and Resources

## Landmark Clinical Trials

### Diabetic Macular Edema

| Trial | Agents | Key Finding |
|-------|--------|-------------|
| RISE/RIDE | Ranibizumab | Established anti-VEGF efficacy for DME |
| VISTA/VIVID | Aflibercept | Aflibercept non-inferior/superior to laser |
| Protocol T (DRCR.net) | Aflibercept vs. Ranibizumab vs. Bevacizumab | Similar efficacy at 2 years; aflibercept superior for poor baseline VA |
| Protocol V (DRCR.net) | Observation vs. Aflibercept for good VA CI-DME | Observation acceptable for 20/25 or better |
| YOSEMITE/RHINE | Faricimab | Extended durability up to q16 weeks |
| PHOTON | Aflibercept HD (8mg) | Extended dosing intervals |

---

### Age-Related Macular Degeneration

| Trial | Agents | Key Finding |
|-------|--------|-------------|
| MARINA/ANCHOR | Ranibizumab | Established anti-VEGF for nAMD |
| CATT | Ranibizumab vs. Bevacizumab | Similar efficacy |
| VIEW 1/2 | Aflibercept | Non-inferior to monthly ranibizumab |
| HAWK/HARRIER | Brolucizumab | Extended durability; IOI signal |
| TENAYA/LUCERNE | Faricimab | Non-inferior with extended intervals |
| OAKS/DERBY | Pegcetacoplan | First approved treatment for GA |
| GATHER | Avacincaptad pegol | Alternative GA treatment |

---

### Retinal Vein Occlusion

| Trial | Agents | Indication |
|-------|--------|------------|
| BRAVO | Ranibizumab | BRVO macular edema |
| CRUISE | Ranibizumab | CRVO macular edema |
| COPERNICUS/GALILEO | Aflibercept | CRVO macular edema |
| VIBRANT | Aflibercept | BRVO macular edema |
| SCORE2 | Bevacizumab vs. Aflibercept | Non-inferior efficacy |

---

## Professional Society Guidelines

### American Academy of Ophthalmology (AAO)

**Preferred Practice Patterns**:
- Diabetic Retinopathy PPP
- Age-Related Macular Degeneration PPP
- Retinal Vein Occlusions PPP

**Website**: www.aao.org/preferred-practice-pattern

---

### EURETINA

**Clinical Guidelines**:
- nAMD Management Guidelines
- DME Management Guidelines
- RVO Management Guidelines

**Website**: www.euretina.org

---

### American Society of Retina Specialists (ASRS)

**Resources**:
- Preferences and Trends Survey
- Clinical updates

**Website**: www.asrs.org

---

## Key Classification Systems

### AMD Classification

**Beckman Classification (2013)**:
- Ferris FL, et al. Ophthalmology 2013;120:844-851
- Standardized AMD staging

**Classification of Atrophy Meetings (CAM)**:
- Sadda SR, et al. Ophthalmology 2018
- OCT-based GA classification

---

### OCT Nomenclature

**IN-OCT Consensus (2014)**:
- Staurenghi G, et al. Ophthalmology 2014;121:1572-1578
- International standardized OCT terminology
- Defines EZ, IZ, ELM terminology

---

### Diabetic Retinopathy

**ETDRS Severity Scale**:
- Early Treatment Diabetic Retinopathy Study
- Standard for DR staging

**International Clinical DR Scale**:
- Simplified 5-level scale
- Widely used clinically

---

## Biomarker Research

### Systematic Reviews and Meta-Analyses

**DME Biomarkers**:
- "Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-analysis" (2025)
- Evaluated 75 biomarkers from 27 studies

**AMD Progression Biomarkers**:
- "OCT Prognostic Biomarkers for Progression to Late Age-Related Macular Degeneration" (2024)
- 114 quantified OCT biomarkers

**RVO Biomarkers**:
- "Predicting treatment response in retinal vein occlusions using baseline optical coherence tomography biomarkers" (2025)
- 31 unique biomarkers evaluated

---

## Imaging Technology Resources

### OCT Platforms

| Manufacturer | Platform | Key Features |
|--------------|----------|--------------|
| Zeiss | Cirrus HD-OCT | Wide install base, AngioPlex OCTA |
| Heidelberg | Spectralis | Eye tracking, EDI capability |
| Topcon | Triton/Maestro | Swept-source OCT |
| Optovue | Avanti | AngioVue OCTA |
| Canon | OCT-HS100 | High-speed imaging |

---

### OCTA Resources

**Educational Materials**:
- AAO Ophthalmic News and Education (ONE) Network
- Device-specific training modules
- ASRS educational content

---

## Educational Websites

### EyeWiki (AAO)
- eyewiki.org
- Peer-reviewed ophthalmic encyclopedia
- OCT and OCTA articles

### Retina Today
- retinatoday.com
- Clinical updates and reviews

### Review of Ophthalmology
- reviewofophthalmology.com
- Practice-focused content

### Ophthalmology Retina (Journal)
- www.ophthalmologyretina.org
- Peer-reviewed research

---

## Continuing Education

### CME Resources

- AAO Annual Meeting
- ASRS Annual Meeting
- Retina Society Meeting
- Macula Society Meeting
- Online CME platforms

---

## Image Databases and Atlases

### OCT Atlases

**Published Resources**:
- "Atlas of OCT: Retinal Anatomy in Health & Pathology" - Heidelberg Engineering
- Various device-specific reference guides

### Online Resources

- Ophthalmic Photographers' Society
- Device manufacturer educational portals
- University-based teaching files

---

## Research Networks

### DRCR Retina Network
- drcrnet.org
- Leading clinical trials for diabetic eye disease
- Protocol publications freely available

### Writing Committees and Consensus Groups

- IN-OCT (International Nomenclature for OCT)
- CAM (Classification of Atrophy Meetings)
- Various disease-specific working groups

---

## Regulatory Information

### FDA Approved Treatments

**Anti-VEGF Agents**:
- Check FDA.gov for current labeling
- Indications, dosing, safety information

**Complement Inhibitors for GA**:
- Pegcetacoplan (Syfovre)
- Avacincaptad pegol (Izervay)

---

## Suggested Reading for Key Topics

### OCT Biomarkers
1. Schmidt-Erfurth U, et al. "A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration." Prog Retin Eye Res. 2017
2. Browning DJ, et al. "OCT in Diabetic Macular Edema." Various publications

### OCTA Applications
1. Spaide RF, et al. "Optical Coherence Tomography Angiography." Prog Retin Eye Res. 2018

### Pachychoroid Spectrum
1. Dansingani KK, et al. "Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy)." Prog Retin Eye Res. 2018

### MacTel
1. Charbel Issa P, et al. "Macular telangiectasia type 2." Prog Retin Eye Res. 2013

---

## Version Notes

This reference document represents literature through early 2025. Medical knowledge evolves rapidly; always verify current guidelines before making clinical decisions.

---

## Cross-References

- Treatment protocols: `treatment-protocols.md`
- Disease analysis: `../procedures/disease-analysis.md`
- Biomarkers overview: `../core-concepts/biomarkers-overview.md`
